Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

Overview of attention for article published in Molecular Cancer Therapeutics, November 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

So far, Altmetric has seen 8 X posts from 4 X users, with an upper bound of 2,848 followers.

RT @MCT_AACR: Evaluation of preclinical activity of #osimertinib shows that it inhibits signaling pathways and #CellularGrowth in various p…

Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various P… https://t.co/XsvbGjqC8G

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.